-
To avoid any misunderstanding, I would like to clarify the distinction I am drawing. I am not questioning the adequacy of your processes or suggesting anything is being done incorrectly. My enquiry relates solely to the type of recorded assurance held by your organisation. You note that the Agency receives outcome based reports and certificates from third party suppliers. A certificate or record confirming that an erasure process was applied demonstrates that a recognised method was used. What I am seeking to understand is whether your organisation holds any recorded evidence of the outcome, namely evidence that the data on a specific storage device is irrecoverable following erasure, rather than confirmation that the erasure process was executed. With that distinction in mind, please confirm: 1. Do the IT asset disposal certificates or related contractual terms held by your organisation constitute an explicit outcome based warranty or guarantee that the personal data on each specific storage device has been rendered irrecoverable as a final data state, or do they primarily confirm that a certified erasure process was followed? 2. Beyond reliance on supplier accreditation, recognised standards including but not limited to ADISA certification, ISO accreditation, HMG IA standards, or confirmation that an erasure process was completed, does your organisation hold any recorded, device specific documentation evidencing independent verification, testing, or validation that the data on the particular storage media processed has been rendered irrecoverable in practice? For clarity, this request relates specifically to recorded outcome evidence demonstrating irrecoverability of data on the individual storage device, not documentation confirming that an accredited or certified method was applied. If no explicit outcome based warranty or device specific outcome evidence is held beyond certification, accreditation, or confirmation of process completion, please confirm accordingly. I am not seeking technical configuration detail, only clarification of the recorded assurance basis relied upon when concluding irrecoverability of the final data state.
Published: 6 May 2026
-
Thank you for your response dated 3 March 2026 and for the guidance regarding the cost limit under Section 12. To assist the MHRA in providing a response within the appropriate limit, I am refining the scope of my request. Instead of all psychiatric disorders, I request that the MHRA provides the requested information for one of the following two representative SSRI medications. Please choose the one that is most easily accessible within your records to satisfy the cost limit: • Option A: Fluoxetine (Prozac) – representing the foundational SSRI approval. • Option B: Sertraline (Lustral/Zoloft) – representing a widely prescribed modern SSRI. For the chosen medication, please provide clear YES/NO answers and specific document references for the following: 1. Measurable Biological Cause: Does the MHRA possess any documentation (e.g., from the initial Marketing Authorisation or subsequent reviews) that identifies a specific, measurable biological abnormality or biomarker in patients that the medication is intended to correct? 2. Biological Normalisation: Does the MHRA possess documentation demonstrating that the therapeutic effect of the medication is clinically proven to "normalise" or "balance" a pre-existing and measured neurochemical deficiency (e.g., serotonin levels)? 3. Clinical Thresholds: Does the MHRA possess documents specifying the "normal clinical range" or "threshold values" for serotonin levels used to define the disease state for which the medication is prescribed? 4. Scientific Rationale for Prescription: Does the MHRA possess any document explaining the scientific rationale for why diagnostic biological measurements (e.g., neurotransmitter levels) are not required or performed before the medication is initiated? If the MHRA maintains that this information is only available within specific Public Assessment Reports (PARs), please provide the direct reference or document title for the specific PAR where the scientific evidence for the biological cause/correction is documented for the chosen drug. I look forward to your response within the statutory timeframe.
Published: 6 May 2026
-
This is a request under the Freedom of Information Act 2000. Please provide the following information relating to Exchange Supplies Ltd, WDA 50350: • Whether MHRA received any Wholesale Dealer's Authorisation application from Exchange Supplies Ltd for any premises between 1 July 2025 and the date of this request • If so, the date the application was received, the address of the premises named in the application, and the current status of that application • Whether any such application was linked to or cross-referenced with case CEC 227535 in MHRA's case management system • Whether the decision not to take enforcement action in case CEC 227535 was made before or after any such application was received
Published: 6 May 2026
-
Were HSCNI notified that prescription only medicines were being supplied to their harm reduction contracts from unlicensed premises? Please restrict your search to emails sent from members of the following teams only: • The Criminal Enforcement team within MHRA's Compliance unit • The Good Distribution Practice team within MHRA's Compliance unit Please include emails sent to any @hscni.net domain including but not limited to @southerntrust.hscni.net and @setrust.hscni.net, covering the period 1 July 2025 to 31 December 2025. If the cost limit is still exceeded following this narrowing, please contact me before refusing and advise what further narrowing would bring the request within scope.
Published: 6 May 2026
-
Please provide the following information under the Freedom of Information Act 2000: 1. Total income received by CPRD from commercial data licences (including real‑world evidence services and data access fees) for the financial years 2021–22, 2022–23, 2023–24, and any more recent financial year for which data is available. 2. The total volume or proportion of CPRD primary care data (i.e., data extracted from GP practices) that has been used for commercial purposes in the last 12 months. If possible, please specify this as either the number of commercial projects, the volume of data records, or any metric routinely used by CPRD. 3. The total amount of money returned to HM Treasury from CPRD/MHRA surpluses for the most recent financial year available. If recorded separately, please indicate the specific amount attributable to CPRD.
Published: 6 May 2026
-
This is a request under the Freedom of Information Act 2000. Context On 10 July 2025 I made a protected disclosure to MHRA regarding Exchange Supplies Ltd, WDA 50350, reference CEC 227535. My disclosure included Business Central ERP records evidencing 1,179 individual orders of prescription only medicines including Naloxone and sterile water for injection dispatched from unlicensed Romans Building to Health and Social Care Northern Ireland between April 2022 and October 2024 under public health harm reduction contracts. Please provide all recorded information held by MHRA relating to the following: 1. Communications between MHRA and HSCNI regarding Exchange Supplies Ltd * Any communications between MHRA and HSCNI regarding Exchange Supplies Ltd, WDA 50350, or the supply of medicines from Romans Building, Groove Trading Estate, Dorchester DT1 1ST * Any notification sent to HSCNI regarding compliance failures affecting their supply chain * Any response received from HSCNI * Any risk assessment conducted regarding the supply of Naloxone and sterile water for injection from unlicensed premises to HSCNI harm reduction contracts * If no communication was made to HSCNI, confirmation in writing that HSCNI was not notified Formats Please include emails, letters, case management records, notes and internal communications as defined by FOIA s.84.
Published: 6 May 2026
-
We would like to request copies of the below documents related to the reclassifications of famotidine 10mg / Pepcid AC (Famotidine 10mg; PL 00025/0312 (Merck, Sharp & Dohme Limited, Hoddesdon, UK) from; a) a POM to P medicine (1994) and from; b) a P to GSL medicine (2000) Requested documents: 1) Copies of the reclassification submission documents (redacted if necessary) 2) Copies of the assessors’ report (redacted if necessary) 3) Associated Annexes to the report 4) Stakeholder comments to the reclassification (or summary of these if appropriate) 5) Copies of any educational materials approved with either of these switch applications
Published: 6 May 2026
-
I am writing a Freedom of Information request in order to request the following for product, Diprosalic Scalp Application 0.05% w/w / 2% w/w, cutaneous solution (PL 00025/0569): * Please can you confirm the legal basis and route of authorisation? * Please can you confirm the licencing history? * Please can you provide the public assessment report?
Published: 6 May 2026
-
I am emailing for an updated FOI request for all the information in the below report (FOI 22/480) ran from its run date of 09/03/2022 to present day. All UK spontaneous suspected adverse drug reaction reports received between 09/03/2022 and March 2026 for the Human Papilloma virus vaccine https://assets.publishing.service.gov.uk/media/62975e978fa8f503921c1535/FOI_22_480-1.pdf#:~:text=FOI%2022/480%20%2D%20HPV%20vaccine:%20All%20UK,received%20between%2018/02/2007%20and%2018/02/2022%20for%20the.
Published: 6 May 2026
-
Medicine used for cancer treatments (pills, liquids medicines etc), with a breakdown of this, that have been seized. These are the brand/drugs names for clarification: Iclusig (brand) ponatinib (drug) IMFINZI Casodex (brand) bicalutamide (drug) Adcetris (brand) brentuximab vedotin (drug)
Published: 6 May 2026
